First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection-Reference-Cited by-同舟云学术

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection

Published:2020-07-08 Issue:2 Volume:87 Page:598-611
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Bergougnan Luc¹,Armani Sara²,Golor Georg²,Tardat Agnes³,Vitse Olivier³,Hurbin Fabrice³^ORCID,Scemama Michel¹,Poitiers Franck¹,Radzik David¹,Gaudin Christophe¹,Hovsepian Lionel¹,Muslin Anthony J.⁴,Kirkesseli Stephane¹,Deutsch Paul⁵,Parkar Ashfaq A.⁵^ORCID

Affiliation:

1. Sanofi R&D Chilly Mazarin France

2. Parexel International GmBH Berlin Germany

3. Sanofi R&D Montpellier France

4. Sanofi US Services Cambridge MA USA

5. Sanofi US Services Bridgewater NJ USA

Funder

Sanofi

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology